Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety, tolerability, and effectiveness of adding metformin to standard multidrug therapy MDT for patients newly diagnosed with multibacillary leprosy. This double-blind, placebo-controlled Phase 2 trial aims to see if metformin can reduce leprosy reactions, nerve damage, and corticosteroid use while assessing immunological responses. The study is supported by the Leprosy Research Initiative and conducted in Indonesia with participants aged 18 to 65. Participants will be randomly assigned to receive either metformin or a placebo once daily. Metformin dosing starts at 500mg for two weeks, then increases to 1000mg for 22 weeks, alongside 48 weeks of standard MDT. The placebo group receives matching tablets to maintain blinding. The trial plans to enroll 166 patients to compare clinical outcomes between the two groups. During the 48-week study, participants will be regularly monitored for leprosy reactions, adverse events, nerve function, corticosteroid use, and quality of life through clinical assessments and questionnaires. The primary outcomes include the proportion of patients experiencing leprosy reactions and adverse events within specified timeframes. Secondary outcomes focus on reaction severity, timing, frequency, and impact on daily living. Safety and tolerability will also be closely observed throughout the study period.
Actively Recruiting
Researchers are investigating the optimal dose of tafenoquine for treating Plasmodium vivax malaria in Southeast Asia. This study compares the current recommended 300 mg dose of tafenoquine, which is less effective in this region, to a 50% higher dose. The trial also includes a comparison to high-dose primaquine in Indonesia, where primaquine is the standard care. The goal is to improve radical cure rates by reducing malaria recurrence. Participants will be randomly assigned to receive either the standard tafenoquine dose or a higher dose, both given as a single dose adjusted by weight bands. In Indonesia, a third group will receive high-dose primaquine daily for seven days. All participants will receive a schizonticidal agent such as chloroquine or artemether-lumefantrine alongside tafenoquine or primaquine. Drug administration will be directly observed to ensure adherence, and the treatments are given according to the national malaria guidelines. Participants will be followed daily until malaria parasites clear and then at several scheduled visits up to 4 months. These visits include blood tests, physical exams, and monitoring of adverse events and drug levels. If malaria recurs, treatment and follow-up restart as a new episode. The study measures include recurrence of infection by microscopy and molecular methods, adverse events, and drug levels over time. Data confidentiality and quality control procedures are in place, with a total participation duration of 4 months per episode.